{"id":5732,"date":"2024-06-19T09:05:13","date_gmt":"2024-06-19T14:05:13","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5732"},"modified":"2025-06-27T11:16:41","modified_gmt":"2025-06-27T16:16:41","slug":"nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","title":{"rendered":"Nanoscope Therapeutics participar\u00e1 en Leerink Partners Biopharma Private Company Connect 2024"},"content":{"rendered":"<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<div class=\"col-sm-8 col-vcenter col-xs-12\">\n<h1><\/h1>\n<\/div>\n<\/div>\n<\/div>\n<article class=\"news-release inline-gallery-template\">\n<section class=\"release-body container\">\n<div class=\"row\">\n<div class=\"col-lg-10 col-lg-offset-1\">\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">DALLAS<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">18 de junio de 2024<\/span><\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (AMD), anunci\u00f3 hoy que la gerencia participar\u00e1 en reuniones individuales con inversionistas en Leerink Partners Biopharma Private Company Connect 2024. retenido virtualmente en\u00a0<span class=\"xn-chron\">25 y 26 de junio de 2024<\/span>.<\/p>\n<p><b>Acerca de Nanoscope Therapeutics Inc.<\/b><\/p>\n<p>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas que restauran la vista y son independientes de los genes para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2024\/03\/26\/nanoscope-therapeutics-announces-top-line-results-from-ph2-trial-of-mco-010-for-retinitis-pigmentosa\/\" target=\"_blank\" rel=\"nofollow noopener\">anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0la fase de RESTAURACI\u00d3N\u00a0<span class=\"xn-money\">2b<\/span>\/3 ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinosis pigmentaria (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4192527-1&amp;h=3393632503&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D4290035820%26u%3Dhttps%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3984630-1%26h%3D517760235%26u%3Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fct2%2525252Fshow%2525252FNCT04945772%2525253Fterm%2525253DNanoscope%25252526draw%2525253D2%26a%3DNCT04945772%26a%3DNCT04945772&amp;a=NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes con enfermedad de Stargardt (<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4192527-1&amp;h=2980886663&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4009878-1%26h%3D736901417%26u%3Dhttps%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D3984630-1%26h%3D1090222651%26u%3Dhttps%2525253A%2525252F%2525252Fclinicaltrials.gov%2525252Fct2%2525252Fshow%2525252FNCT05417126%2525253Fterm%2525253Dnanoscope%25252526draw%2525253D2%25252526rank%2525253D3%26a%3DNCT05417126%26a%3DNCT05417126&amp;a=NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>\u00a0). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la DMAE.<\/p>\n<p><b>Contacto de inversores:<\/b><br class=\"dnr\" \/>Socios Argot<br class=\"dnr\" \/>212-600-1902<br class=\"dnr\" \/><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/p>\n<p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"<p>DALLAS,\u00a0June 18, 2024\u00a0 &#8212; Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that management will participate in one-on-one meetings with investors at the 2024 Leerink Partners Biopharma Private Company Connect, being held virtually on\u00a0June 25-26, 2024. About Nanoscope Therapeutics Inc. Nanoscope [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":5733,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5732","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-06-19T14:05:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:16:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect\",\"datePublished\":\"2024-06-19T14:05:13+00:00\",\"dateModified\":\"2025-06-27T16:16:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"},\"wordCount\":180,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\",\"name\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"datePublished\":\"2024-06-19T14:05:13+00:00\",\"dateModified\":\"2025-06-27T16:16:41+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/06\\\/NSCOPE_LI_Leerink2024REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/06\\\/19\\\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics participar\u00e1 en el evento Leerink Partners Biopharma Private Company Connect 2024 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-06-19T14:05:13+00:00","article_modified_time":"2025-06-27T16:16:41+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect","datePublished":"2024-06-19T14:05:13+00:00","dateModified":"2025-06-27T16:16:41+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"},"wordCount":180,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","url":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/","name":"Nanoscope Therapeutics participar\u00e1 en el evento Leerink Partners Biopharma Private Company Connect 2024 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","datePublished":"2024-06-19T14:05:13+00:00","dateModified":"2025-06-27T16:16:41+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/06\/NSCOPE_LI_Leerink2024REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/06\/19\/nanoscope-therapeutics-to-participate-in-the-2024-leerink-partners-biopharma-private-company-connect\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Participate in the 2024 Leerink Partners Biopharma Private Company Connect"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5732","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5732"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5732\/revisions"}],"predecessor-version":[{"id":9043,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5732\/revisions\/9043"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5733"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5732"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5732"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5732"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}